You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Disitamab vedotin

Showing 26 - 50 of 280
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Colorectal Cancer Trial (Anti-HER2 ADC)

Not yet recruiting
  • Colorectal Cancer
  • Anti-HER2 ADC
  • (no location specified)
Oct 12, 2022

Biliary Carcinoma Trial in Nanjing (Disitamab Vedotin combined with Zimberelizumab)

Recruiting
  • Biliary Carcinoma
  • Disitamab Vedotin combined with Zimberelizumab
  • Nanjing, Jiangsu, China
    Jiangsu Province Hospital
Sep 14, 2022

Breast Cancer, Neoadjuvant Therapy Trial in Wuhan (Disitamab Vedotin combined with Tislelizumab)

Recruiting
  • Breast Cancer
  • Neoadjuvant Therapy
  • Disitamab Vedotin combined with Tislelizumab
  • Wuhan, Hubei, China
    WuhanHU
May 16, 2023

HER2-positive Gastric Cancer Trial in Jinan, Qingdao, Yantai (Disitamab vedotin, Tislelizumab, S1)

Not yet recruiting
  • HER2-positive Gastric Cancer
  • Disitamab vedotin
  • +2 more
  • Jinan, Shandong, China
  • +6 more
Oct 16, 2022

Gastric Cancer Trial (Disitamab Vedotin Combined With PD-1 and Neoadjuvant Chemotherapy)

Not yet recruiting
  • Gastric Cancer
  • Disitamab Vedotin Combined With PD-1 and Neoadjuvant Chemotherapy
  • (no location specified)
Nov 8, 2021

Urothelial Carcinoma Trial in United States (disitamab vedotin, pembrolizumab)

Recruiting
  • Urothelial Carcinoma
  • Los Angeles, California
  • +17 more
Jan 3, 2023

Esophageal Squamous Carcinoma, HER-2 Protein Overexpression Trial (RC48+PD-1+platinum-based)

Not yet recruiting
  • Esophageal Squamous Carcinoma
  • HER-2 Protein Overexpression
  • (no location specified)
Sep 24, 2023

Non-Muscle Invasive Bladder Cancer, HER2 Trial (RC48, Tislelizumab)

Not yet recruiting
  • Non-Muscle Invasive Bladder Cancer
  • HER2
  • (no location specified)
Jul 16, 2023

Metastatic Castration-resistant Prostate Cancer Trial (Disitamab Vedotin(RC48-ADC))

Not yet recruiting
  • Metastatic Castration-resistant Prostate Cancer
  • Disitamab Vedotin（RC48-ADC）
  • (no location specified)
Jul 13, 2023

HER2-overexpressed Advanced Solid Tumors After Progression of

Not yet recruiting
  • HER2
  • +3 more
  • Disitamab Vedotin
  • Beijing, Beijing, China
    Beijing Cancer Hospital
Dec 14, 2022

Cervical Cancer Trial in China (Disitamab Vedotin, Zimberelimab)

Not yet recruiting
  • Cervical Cancer
  • Bengbu, Anhui, China
  • +11 more
Nov 23, 2023

Gastric Cancer Trial in Beijing (RC48-ADC, Herceptin, Toripalimab)

Not yet recruiting
  • Gastric Cancer
  • Beijing, China
    Beijing Cancer Hospital
Aug 7, 2023

Muscle Invasive Bladder Carcinoma Trial in Beijing (RC48-ADC, AK104)

Recruiting
  • Muscle Invasive Bladder Carcinoma
  • Beijing, China
    Cancer Institute and Hospital, Chinese Academy of Medical Scienc
Oct 6, 2023

Muscle Invasive Bladder Cancer, HER2 Expression, Radiotherapy Trial in Shanghai (Disitamab Vedotin and Toripalimab)

Recruiting
  • Muscle Invasive Bladder Cancer
  • +4 more
  • Disitamab Vedotin and Toripalimab
  • Shanghai, Shanghai, China
    Renji Hospital, School of Medicine, Shanghai Jiao Tong Universit
Jul 31, 2023

Advanced Gastric Carcinoma, HER2-positive Gastric Cancer Trial in ZhengZhou (RC48+AK105+cisplatin)

Not yet recruiting
  • Advanced Gastric Carcinoma
  • HER2-positive Gastric Cancer
  • ZhengZhou, Henan, China
    Henan Cancer Hospital/The affiliated Cancer Hospital of ZhengZho
Mar 29, 2022

Urothelial Carcinoma, HER2-expressing Trial in Beijing (RC48-ADC, Toripalimab, Gemcitabine)

Not yet recruiting
  • Urothelial Carcinoma
  • HER2-expressing
  • Beijing, Beijing, China
  • +1 more
Apr 2, 2022

Bladder Cancer Trial in Nanjing (RC48-ADC, Triplizumab)

Not yet recruiting
  • Bladder Cancer
  • Nanjing, Jiangsu, China
    The Affiliated Nanjing Drum Tower Hospital of Nanjing University
Aug 20, 2021

Carcinoma, Upper Tract Urothelial Carcinoma, UTUC Trial in Nanjing (RC48-ADC and JS001)

Recruiting
  • Carcinoma
  • +2 more
  • RC48-ADC and JS001
  • Nanjing, Jiangsu, China
    Jinling Hospital, Affiliated Hospital of Medical School, Nanjing
Jun 15, 2023

Metastatic Penile Squamous Cell Carcinoma, Stage III Penile Cancer AJCC v8, Stage IV Penile Cancer AJCC v8 Trial in Phoenix,

Not yet recruiting
  • Metastatic Penile Squamous Cell Carcinoma
  • +3 more
  • Enfortumab Vedotin
  • Phoenix, Arizona
  • +2 more
Oct 23, 2023

DLBCL, Not Otherwise Specified, High Grade B-Cell Lymphoma, Transformed Indolent B-Cell Non-Hodgkin Lymphoma to DLBCL Trial

Not yet recruiting
  • Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
  • +2 more
  • Biospecimen Collection
  • +5 more
  • (no location specified)
Sep 5, 2023

Solid Malignancies Trial (Tisotumab Vedotin)

Not yet recruiting
  • Solid Malignancies
  • Tisotumab Vedotin
  • (no location specified)
May 9, 2023

Renal Pelvis and Ureter Urothelial Carcinoma Trial in Los Angeles (procedure, drug, biological)

Not yet recruiting
  • Renal Pelvis and Ureter Urothelial Carcinoma
  • Biopsy
  • +5 more
  • Los Angeles, California
    UCLA / Jonsson Comprehensive Cancer Center
Mar 15, 2023

Bladder Squamous Cell Carcinoma, Locally Advanced Bladder Carcinoma, Malignant Renal Pelvis Tumor Trial in Atlanta (procedure,

Not yet recruiting
  • Bladder Squamous Cell Carcinoma
  • +10 more
  • Biospecimen Collection
  • +5 more
  • Atlanta, Georgia
  • +3 more
Feb 20, 2023

Breast Cancer Trial in Nanjing (Disitamb Vedotin ,pyrotinib)

Not yet recruiting
  • Breast Cancer
  • Disitamb Vedotin ,pyrotinib
  • Nanjing, Jiangsu, China
    Jiangsu Provincial People's Hospital
Aug 18, 2023

Cutaneous T-cell Lymphoma Retreated With Brentuximab Vedotin

Not yet recruiting
  • T-Cell Lymphoma
  • No intervention
  • Bordeaux, France
  • +10 more
May 24, 2023